Herbst Kinsky – longstanding advisor of Hookipa Biotech AG – advised the company in connection with an oversubscribed series C financing round in the amount of EUR 50 mio. Lead investor was a blue chip U.S. public investment fund together with the new investors HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. All current Hookipa investors, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners participated in the round.

Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology. The proceeds of the fundraising will be primarily used to progress two proof-of concept clinical trials of Hookipa’s lead development programs.

“Transactions like this are the proof that our long term specialization in venture capital and in particular in biotech was the right decision. Only therefore our know-how and experience contribute to success and our clients can be supported in the best possible way”, says Philipp Kinsky, partner at Herbst Kinsky. Philipp Kinsky has led transaction with the support of David Pachernegg (attorney) and Felix Kernbichler (associate).